Immunotherapy for Lung Cancer and Other Solid Tumors: Patient Selection With NGS and Molecular Profiling

Immunotherapy for Lung Cancer and Other Solid Tumors: Patient Selection With NGS and Molecular Profiling

Quick Answer: Cancer immunotherapy produces durable tumor control in roughly 20% to 40% of unselected patients. Next-generation sequencing (NGS) and comprehensive molecular profiling identify specific predictive biomarkers-such as PD-L1 expression, microsatellite instability (MSI-H/dMMR), and high tumor mutational burden (TMB)-to ensure clinicians prescribe checkpoint inhibitors only when a patient's immune system can actively detect the malignancy.

Key Takeaways:

• Molecular profiling prevents the inappropriate use of immunotherapy in patients with targetable driver mutations (such as EGFR or ALK), directing them toward targeted therapies instead.
• High PD-L1 expression, high microsatellite instability (MSI-H), and high tumor mutational burden (TMB-H) serve as the primary clinical markers for checkpoint inhibitor eligibility.
• Malignancies with high baseline mutation rates, including non-small cell lung cancer, cutaneous melanoma, and urothelial carcinoma, yield the highest objective response rates.
• Immune-related adverse events differ fundamentally from chemotherapy side effects, presenting as autoimmune inflammation in organs such as the colon, lungs, liver, and endocrine glands.
• Immunologically "cold" malignancies, including microsatellite-stable prostate and ovarian cancers, rarely respond to single-agent immunotherapy and require combination treatment strategies.

Cancer immunotherapy is a specialized class of oncologic treatments-most commonly immune checkpoint inhibitors-that enables a patient's own immune system to recognize, target, and eliminate malignant cells. Unlike standard cytotoxic drugs that attack all rapidly dividing cells, immunotherapy modulates T-cell regulatory pathways, allowing immune cells to overcome the evasive signals produced by tumor cells. Comprehensive molecular testing ensures that clinicians administer this therapy only when a tumor displays the specific biological signatures required for an immune-mediated response.

---

How Molecular Profiling and NGS Select the Right Immunotherapy Candidates

Immunotherapy benefits an estimated 20% to 40% of unselected cancer patients; next-generation sequencing (NGS) and comprehensive molecular profiling identify the specific actionable markers that indicate whether the immune system can recognize and attack the tumor.

Next-generation sequencing evaluates hundreds of genes simultaneously from a single tissue biopsy or blood sample (liquid biopsy). This multi-gene approach detects somatic mutations, copy number alterations, structural rearrangements, and genomic instability. By mapping the genomic profile of a tumor, oncologists distinguish between immunogenic tumors that attract cytotoxic T lymphocytes and immunologically silent malignancies that evade immune detection.

Molecular profiling also protects patients from inappropriate treatment pathways. In non-small cell lung cancer, for instance, tumors harboring activating driver alterations-such as EGFR mutations or ALK fusions-frequently express the PD-L1 protein on their surface. Despite this expression, these tumors show low response rates to single-agent PD-1 or PD-L1 inhibitors (typically reported below 10%) while carrying a heightened risk of severe lung inflammation (pneumonitis). Detecting these mutations through upfront NGS directs patients toward targeted tyrosine kinase inhibitors (TKIs), reserving immunotherapy for later treatment lines or combination regimens.

Comprehensive genomic testing standardizes patient selection across several clinical parameters:

• Genomic Instability Assessment: Quantifying microsatellite status and insertion-deletion burdens.
• Total Mutational Load: Measuring somatic coding mutations per megabase of sequenced DNA.
• Negative Predictive Biomarkers: Identifying mutations in STK11, KEAP1, or MDM2 that correlate with primary resistance to checkpoint blockade or rapid disease progression.
• Actionable Driver Identification: Screening for EGFR, ALK, ROS1, RET, MET, and BRAF alterations to prioritize targeted oral therapies.

---

Core Biomarkers in Plain English: PD-L1, MSI-H/dMMR, and High TMB

Three primary molecular signals guide immunotherapy decisions: PD-L1 expression measures immune checkpoint masking, MSI-H/dMMR indicates DNA repair failure that creates visible neoantigens, and high Tumor Mutational Burden (TMB ≥10 mut/Mb) signals abundant targets for cytotoxic T cells.

PD-L1 (Programmed Death-Ligand 1)

PD-L1 is a surface protein found on both cancer cells and tumor-infiltrating immune cells. When PD-L1 binds to the PD-1 receptor on cytotoxic T cells, it sends an inhibitory signal that halts T-cell activity. Pathologists measure PD-L1 using immunohistochemistry (IHC) staining, reporting results through standard scoring systems:

• Tumor Proportion Score (TPS): The percentage of viable tumor cells showing partial or complete membrane staining. A TPS of 50% or higher defines high expression in non-small cell lung cancer.
• Combined Positive Score (CPS): The number of PD-L1-staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100. This score guides clinical decisions in urothelial, gastric, and cervical cancers.

MSI-H / dMMR (Microsatellite Instability-High / Mismatch Repair Deficiency)

Cells use the mismatch repair (MMR) protein system (MLH1, MSH2, MSH6, and PMS2) to correct spontaneous errors made during DNA replication. When this system fails (dMMR), errors accumulate in short, repetitive DNA segments known as microsatellites, resulting in microsatellite instability-high (MSI-H) status. Tumors with MSI-H generate thousands of abnormal peptides (neoantigens). These foreign proteins help circulating immune cells recognize the tumor once checkpoint inhibitors release the brakes on T cells.

TMB (Tumor Mutational Burden)

Tumor Mutational Burden measures the total number of non-synonymous somatic mutations per megabase (mut/Mb) of sequenced tumor DNA. A high mutational burden (clinically defined as TMB ≥10 mut/Mb on validated NGS panels) correlates with increased neoantigen production. Because ultraviolet radiation, cigarette smoke, and defective proofreading enzymes cause widespread DNA alterations, high-TMB tumors present numerous distinct targets for T cells, improving the likelihood of a clinical response to PD-1 and PD-L1 inhibitors.

---

Cancer Types with High Response Rates: Melanoma, Lung, and Bladder Cancers

Malignancies with high baseline mutation rates-such as advanced melanoma cancer immunotherapy candidates, metastatic non-small cell lung cancer, and urothelial bladder cancer immunotherapy cohorts-demonstrate the highest objective response rates to PD-1 and CTLA-4 inhibitors.

Because these tumor types frequently arise from chronic exposure to environmental carcinogens-such as ultraviolet light in skin melanoma and tobacco smoke compounds in non-small cell lung cancer and urothelial carcinoma-they carry high mutational loads. These mutations generate abundant neoantigens, prompting natural infiltration by host cytotoxic T cells.

When clinicians assess patients for melanoma cancer immunotherapy, combination checkpoint blockade (such as nivolumab paired with ipilimumab) yields reported objective response rates exceeding 50% in clinical trials, with long-term survival extending beyond five years in responding cohorts. Blocking both the PD-1 and CTLA-4 pathways restores immune activity during initial T-cell activation in the lymph nodes and within the peripheral tumor site.

In thoracic oncology, immunotherapy for lung cancer has reshaped first-line treatment protocols. Patients with metastatic non-small cell lung cancer and high PD-L1 expression (TPS ≥50%), without targetable driver mutations, frequently receive single-agent pembrolizumab, cemiplimab, or atezolizumab, achieving longer median overall survival than with standard platinum doublet chemotherapy. For patients with PD-L1 scores under 50%, combining checkpoint inhibitors with platinum-based chemotherapy provides higher response rates than chemotherapy alone.

Similarly, advanced bladder cancer immunotherapy protocols incorporate PD-1 and PD-L1 inhibitors for patients who cannot receive cisplatin and for disease that progresses after platinum therapy. Urothelial tumors display marked genomic instability and frequent alterations in chromatin-remodeling genes, making them sensitive to checkpoint inhibitor therapy.

---

Biomarker to Targeted Immunotherapy Matching Table

Treatment choices depend on clear biomarker criteria: high PD-L1 (TPS ≥50%) guides single-agent pembrolizumab in lung cancer, MSI-H/dMMR qualifies solid tumors for tissue-agnostic checkpoint inhibition, while sensitizing EGFR or ALK alterations direct patients to targeted oral therapies instead.

The following clinical decision matrix outlines how molecular biomarkers guide systemic therapy across solid tumors:

Predictive BiomarkerTesting ModalityTarget MalignancyStandard Therapeutic MatchPrimary Clinical RationalePD-L1 TPS ≥50%Immunohistochemistry (IHC)Non-Small Cell Lung CancerPembrolizumab, Cemiplimab, or Atezolizumab (monotherapy)High checkpoint expression without targetable driver mutations predicts response without cytotoxic chemotherapy.MSI-H / dMMRNGS or IHC (MMR panel)Any Solid Tumor (Tissue-Agnostic)Pembrolizumab, DostarlimabAbundant neoantigens from defective DNA repair promote systemic immune recognition across organ sites.TMB-High (≥10 mut/Mb)Validated Comprehensive NGSSolid Tumors, Melanoma, CervicalPembrolizumabHigh somatic mutation density increases the probability of tumor-specific T-cell recognition and clearance.PD-L1 CPS ≥10Immunohistochemistry (IHC)Gastric, GEJ, Triple-Negative BreastCheckpoint inhibitor + Platinum/Fluoropyrimidine chemotherapyCombined score indicates sufficient immune infiltration in the microenvironment to support adding PD-1 blockade.Sensitizing EGFR / ALKComprehensive NGS / RT-PCRNon-Small Cell Lung CancerTargeted TKIs (e.g., Osimertinib, Alectinib); Avoid single-agent PD-1Oncogene-driven tumors show low response to single-agent immunotherapy and carry higher risks of pneumonitis.High Stromal LAG-3IHC / RNA SequencingUnresectable Advanced MelanomaNivolumab + RelatlimabDual checkpoint blockade helps overcome T-cell exhaustion in tumors expressing alternative inhibitory receptors.

---

Managing Autoimmune Side Effects: How Immunotherapy Differs From Chemotherapy

Unlike chemotherapy, which causes direct bone marrow suppression, hair loss, and acute nausea, the primary side effect of immunotherapy for cancer involves immune-related adverse events (irAEs) that occur when an activated immune system attacks healthy tissues, causing inflammation such as colitis, pneumonitis, or thyroiditis.

Pathophysiological Differences

Cytotoxic chemotherapy damages rapidly dividing normal cells, causing temporary drops in white blood cell counts, mouth sores, and hair loss. Immune checkpoint inhibitors instead release the regulatory controls that maintain immune self-tolerance. When these pathways are blocked, autoreactive T cells can infiltrate healthy organ systems and release inflammatory signaling molecules (cytokines) that damage normal tissue.

Common Immune-Related Adverse Events (irAEs)

Immune-related toxicities can develop in any organ during or after treatment:

1. Gastrointestinal (Colitis and Enteritis): Causes frequent watery stools, abdominal pain, and rectal bleeding. Endoscopy usually demonstrates mucosal inflammation and ulceration.
2. Pulmonary (Pneumonitis): Presents with shortness of breath, a dry cough, and low-grade fevers. Chest CT scans typically show ground-glass opacities or organizing pneumonia patterns.
3. Endocrine (Thyroiditis, Hypophysitis, Adrenalitis): Involves immune-mediated injury to hormone-producing glands, resulting in hypothyroidism, hyperthyroidism, adrenal insufficiency, or pituitary inflammation with headaches and vision changes. Most patients require ongoing hormone replacement therapy.
4. Dermatological (Rash and Pruritus): Manifests as red maculopapular patches, itchy skin lesions, or rarely, severe blistering reactions such as Stevens-Johnson syndrome.
5. Hepatic (Autoimmune Hepatitis): Appears as asymptomatic elevations in liver enzymes (ALT, AST) and bilirubin, requiring routine blood monitoring before each infusion.

Toxicity Grading and Clinical Intervention

Oncologists grade irAEs using the Common Terminology Criteria for Adverse Events (CTCAE, Grades 1 to 4):

• Grade 1 (Mild): Mild or asymptomatic changes; treatment continues under regular clinical observation and supportive measures.
• Grade 2 (Moderate): Symptoms interfere with daily activities; clinicians temporarily pause immunotherapy and prescribe oral corticosteroids (such as prednisone at 0.5 to 1 mg/kg/day) until symptoms improve to Grade 1 or resolve.
• Grade 3-4 (Severe or Life-Threatening): Severe symptoms requiring hospital admission; immunotherapy is generally stopped permanently, and high-dose intravenous corticosteroids (methylprednisolone at 1 to 2 mg/kg/day) are started promptly. If symptoms do not improve with steroids, secondary immunosuppressive medications, such as infliximab for colitis or mycophenolate mofetil for hepatitis, are introduced.

---

Why 'Cold' Tumors in Prostate and Ovarian Cancers Face Immunotherapy Resistance

Most prostate cancer immunotherapy protocols and ovarian cancer regimens show modest single-agent activity because these 'cold' tumors carry low mutation rates, dense supportive tissue (stroma), and sparse T-cell infiltration, requiring modern combination strategies to stimulate immune entry.

Mechanisms of Immunological "Coldness"

Immunologically cold tumors-such as microsatellite-stable (MSS) colorectal cancer, pancreatic ductal adenocarcinoma, epithelial ovarian cancer, and metastatic castration-resistant prostate cancer-resist checkpoint inhibitors through established biological factors:

• Low Mutational Burden: These malignancies carry relatively few somatic mutations, creating fewer abnormal proteins for immune cells to detect.
• T-Cell Exclusion: Cancer cells and surrounding fibroblasts release chemical signals (such as TGF-β and VEGF) that create a dense, fibrotic matrix, preventing cytotoxic T cells from reaching the tumor center.
• Immunosuppressive Cell Presence: The local environment recruits regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and supportive macrophages that suppress local immune activity.
• Loss of Antigen Presentation: Loss or reduced expression of Beta-2-Microglobulin (B2M) or HLA class I molecules prevents tumor cells from displaying internal antigens on their outer membrane.

In clinical terms, immunologically "hot" tumors feature high mutational burdens, abundant neoantigens, and strong T-cell infiltration that correlate with checkpoint inhibitor responses. In contrast, immunologically "cold" tumors feature low mutational burdens, fibrotic stroma, and suppressor cells that lead to primary immunotherapy resistance.

Overcoming Immune Resistance

To help convert immunologically cold tumors into responsive ones, oncologists evaluate combination regimens designed to generate neoantigens and facilitate immune cell migration:

• Anti-Angiogenic Combinations: VEGF inhibitors (such as lenvatinib, bevacizumab, or cabozantinib) normalize abnormal tumor blood vessels and decrease suppressor cell recruitment, helping T cells enter the tumor.
• PARP Inhibitor Combinations: In ovarian and prostate tumors with DNA repair defects (such as BRCA1/2 mutations), PARP inhibitors cause DNA breaks that trigger the STING pathway, stimulating interferon release and immune cell recruitment.
• Radiation and Chemotherapy Priming: Focused radiation or low-dose chemotherapy induces immunogenic cell death, releasing tumor antigens that help activate local dendritic cells.
• Targeted Radioligand Therapy: In metastatic prostate cancer, combining PSMA-directed radioligand therapy (such as Lutetium-177 vipivotide tetraxetan) with checkpoint inhibitors delivers targeted radiation that disrupts the tumor architecture and recruits circulating immune cells.

---

Frequently Asked Questions

Can immunotherapy cure cancer?

Immunotherapy does not guarantee a permanent cure for advanced systemic malignancies, but it can achieve long-lasting remissions that continue for years after treatment ends. In responsive tumor types such as advanced melanoma and selected non-small cell lung cancers, a subset of patients achieves sustained complete responses with no visible evidence of active disease on follow-up imaging.

Can immunotherapy cure stage 4 cancer?

Stage 4 cancer is generally treated as a manageable, long-term condition rather than a curable one, though immunotherapy can provide prolonged disease control in eligible patients. In tumors with high PD-L1 levels, MSI-H status, or high mutational burdens, checkpoint inhibitors can control disease progression, extend median survival, and maintain stable health over extended periods.

How long does a patient remain on immunotherapy?

Standard oncologic guidelines generally recommend continuing checkpoint inhibitor therapy for up to two years, provided the tumor remains stable or continues shrinking and the patient does not develop severe immune-related toxicities. If the disease advances or Grade 3-4 side effects develop, oncologists adjust, pause, or discontinue treatment.

Does a negative PD-L1 test rule out all immunotherapy options?

A negative PD-L1 test does not rule out all immunotherapy choices. While single-agent checkpoint inhibitors show lower activity in PD-L1-negative tumors, combining immunotherapy with chemotherapy or targeted anti-angiogenic drugs can produce meaningful clinical responses regardless of baseline PD-L1 levels.

Feel free to upload your full medical records on Voumed.com, so that our AI will match your case with the top matching providers and doctors across our network. This will help you send your case to your preferred clinics/doctors in minutes by translating all your documents into their native language, so that you can receive their reply much sooner and easier.